Blueprint Medicines's Total Assets for the quarter that ended in Mar. 2024 was $1,038.5 Mil.
Warning Sign:
If a company builds assets at 39.5% a year, faster than its revenue growth rate of 26.3% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Blueprint Medicines's average Total Assets Growth Rate was -1.90% per year.
During the past 3 years, the average Total Assets Growth Rate was -26.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 39.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 78.40% per year.
During the past 11 years, Blueprint Medicines's highest 3-Year average Total Assets Growth Rate was 217.30%. The lowest was -26.30%. And the median was 99.60%.
The historical data trend for Blueprint Medicines's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Blueprint Medicines's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blueprint Medicines (NAS:BPMC) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Blueprint Medicines's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Blueprint Medicines Total Assets Related Terms
Thank you for viewing the detailed overview of Blueprint Medicines's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Blueprint Medicines (Blueprint Medicines) Business Description
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BPMC has been successfully added to your 